Overview
Dr. Reitman’s clinical interests include radiotherapy for primary and metastatic tumors of the brain and spine. He is also interested in basic and translational research studies to develop new treatment approaches for pediatric and adult brain tumors. He uses genomic analysis, radiation biology studies, and genetically engineered animal models of cancer to carry out this research
Current Appointments & Affiliations
Assistant Professor of Radiation Oncology
·
2021 - Present
Radiation Oncology,
Clinical Science Departments
Assistant Professor of Pathology
·
2022 - Present
Pathology,
Clinical Science Departments
Assistant Professor in Neurosurgery
·
2022 - Present
Neurosurgery,
Neurosurgery
Member of the Duke Cancer Institute
·
2019 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Combining the RCAS/tv-a retrovirus and CRISPR/Cas9 gene editing systems to generate primary mouse models of diffuse midline glioma.
Journal Article Neoplasia · March 7, 2025 Diffuse midline gliomas (DMGs) are lethal brain tumors that arise in children and young adults, resulting in a median survival of less than two years. Genetically engineered mouse models (GEMMs) are critical to studying tumorigenesis and tumor-immune inter ... Full text Link to item CiteFLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy.
Journal Article Nat Cancer · February 5, 2025 FLASH radiotherapy holds promise for treating solid tumors given the potential lower toxicity in normal tissues but its therapeutic effects on tumor immunity remain largely unknown. Using a genetically engineered mouse model of medulloblastoma, we show tha ... Full text Link to item CiteRadiogenomic explainable AI with neural ordinary differential equation for identifying post-SRS brain metastasis radionecrosis.
Conference Med Phys · January 29, 2025 BACKGROUND: Stereotactic radiosurgery (SRS) is widely used for managing brain metastases (BMs), but an adverse effect, radionecrosis, complicates post-SRS management. Differentiating radionecrosis from tumor recurrence non-invasively remains a major clinic ... Full text Link to item CiteRecent Grants
Role of ATRX deficiency as a determinant of topoisomerase 1 inhibitor sensitivity in high grade gliomas
ResearchCo Investigator · Awarded by American Cancer Society, Inc. · 2025 - 2028Modulation of STING to enhance the efficacy of treatments for diffuse midline glioma
ResearchPrincipal Investigator · Awarded by Alex's Lemonade Stand · 2024 - 2028Enhancing the efficacy of Radiation Therapy for brainstem glioma by targeting ATM
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027View All Grants
Education, Training & Certifications
Duke University, School of Medicine ·
2014
M.D.
Duke University, School of Medicine ·
2012
Ph.D.